Results 111 to 120 of about 22,047 (159)

Extended treatment for venous thromboembolism: Is direct oral anticoagulant dose-reduction better for all? [PDF]

Hemasphere
Lauw MN, Middeldorp S, Carrier M.
europepmc   +1 more source

Relevance and limitations of clinical follow-up in a pharmacokinetic study on direct oral anticoagulants. [PDF]

Front Pharmacol
Terrier J, Gosselin P, Combescure C, Fontana P, Daali Y, Reny JL.   +5 more
europepmc   +1 more source

Trend of Reported Bleeding in Warfarin Compared with Direct Oral Anticoagulants in Japan. [PDF]

Drug Healthc Patient Saf
Takami A, Terashima G, Tajima T, Yamashita K, Igarashi A.   +4 more
europepmc   +1 more source

Stroke and Bleeding Risks With Non-Vitamin K Oral Anticoagulants in Nonvalvular Atrial Fibrillation.

JAMA Netw Open
Bradley MC, Simon AL, Kolonoski J, Graham DJ, Zhang R, Connolly JG.   +5 more
europepmc   +1 more source

Utilization of Apixaban Pharmacokinetics for Dose Optimization in High-Risk Elderly Patients. [PDF]

Clin Pharmacokinet
Goldstein R, Sandouka K, Zighan L, Ya'ari S, Bialer M, Muszkat M.   +5 more
europepmc   +1 more source

Comparative risk of nonvertebral fractures associated with oral anticoagulants in patients with venous thromboembolism. [PDF]

Am J Epidemiol
Zeng Z, Bea S, Sreedhara SK, Bykov K.
europepmc   +1 more source

Scoping review of apixaban and rivaroxaban dosing for atrial fibrillation and venous thromboembolism in advanced chronic kidney disease. [PDF]

Int J Clin Pharm
Gillis S, Phelan E, Pitman J, Trenaman S, Battistella M, Sanyal C, Daley C, Tennankore K, Gillis L, Wilson JA.   +9 more
europepmc   +1 more source